Donald Bergstrom Sells 8,660 Shares of Relay Therapeutics (NASDAQ:RLAY) Stock

Posted by Brenda Bartman on Jul 10th, 2026

Relay Therapeutics, Inc. (NASDAQ:RLAY – Get Free Report) insider Donald Bergstrom sold 8,660 shares of the firm’s stock in a transaction on Monday, July 6th. The stock was sold at an average price of $18.71, for a total value of $162,028.60. Following the transaction, the insider owned 409,897 shares in the company, valued at approximately $7,669,172.87. This trade represents a 2.07% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Relay Therapeutics Price Performance

Shares of NASDAQ:RLAY opened at $20.75 on Friday. Relay Therapeutics, Inc. has a 1 year low of $3.03 and a 1 year high of $20.79. The company’s 50 day simple moving average is $15.16 and its 200 day simple moving average is $11.89. The stock has a market capitalization of $3.98 billion, a price-to-earnings ratio of -13.22 and a beta of 1.67.

Relay Therapeutics (NASDAQ:RLAY – Get Free Report) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.06). The company had revenue of $3.00 million for the quarter, compared to analyst estimates of $5.58 million. As a group, analysts anticipate that Relay Therapeutics, Inc. will post -1.55 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Commodore Capital LP boosted its stake in Relay Therapeutics by 27.3% during the third quarter. Commodore Capital LP now owns 17,000,000 shares of the company’s stock valued at $88,740,000 after buying an additional 3,650,000 shares during the period. Casdin Capital LLC boosted its holdings in Relay Therapeutics by 14.7% during the 4th quarter. Casdin Capital LLC now owns 13,003,574 shares of the company’s stock valued at $110,010,000 after acquiring an additional 1,662,193 shares during the period. Perceptive Advisors LLC boosted its stake in shares of Relay Therapeutics by 412.3% during the first quarter. Perceptive Advisors LLC now owns 9,751,141 shares of the company’s stock valued at $97,024,000 after purchasing an additional 7,847,896 shares during the period. Vanguard Group Inc. boosted its position in Relay Therapeutics by 3.1% during the 4th quarter. Vanguard Group Inc. now owns 9,691,445 shares of the company’s stock valued at $81,990,000 after buying an additional 295,701 shares during the period. Finally, Bellevue Group AG boosted its holdings in shares of Relay Therapeutics by 1.4% during the third quarter. Bellevue Group AG now owns 8,345,610 shares of the company’s stock worth $43,564,000 after purchasing an additional 114,740 shares during the period. Institutional investors own 96.98% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on RLAY. JonesTrading raised Relay Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 19th. HC Wainwright upped their target price on shares of Relay Therapeutics from $25.00 to $28.00 and gave the stock a “buy” rating in a report on Tuesday, May 26th. Oppenheimer raised their price objective on Relay Therapeutics from $14.00 to $18.00 and gave the company an “outperform” rating in a research note on Tuesday, April 28th. Guggenheim lifted their target price on shares of Relay Therapeutics from $22.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, May 26th. Finally, Barclays lifted their target price on Relay Therapeutics from $21.00 to $27.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 20th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $23.73.

View Our Latest Stock Report on RLAY

Relay Therapeutics Company Profile

(Get Free Report)

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.